Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment

Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment

Show other versions (1)

Bibliographic Details
Main Authors:	Daniel J. Bromberg, Samy J. Galvez de Leon, Taylor Litz, Lyu Azbel, Amanda R. Liberman, Maxim Polonsky, Sergii Dvoriak, Nataliia Saichuk, Faye Taxman, Frederick L. Altice
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2023-01-01
Series:	PLOS Global Public Health
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619786/?tool=EBI

Similar Items

Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment.
by: Daniel J Bromberg, et al.
Published: (2023-01-01)

Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial
by: Oleksandra Pashchenko, et al.
Published: (2022-01-01)

Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial.
by: Oleksandra Pashchenko, et al.
Published: (2022-01-01)

Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey
by: Daniel J. Bromberg, et al.
Published: (2024-01-01)

Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
by: Daniel J Bromberg, et al.
Published: (2024-01-01)

Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund support
by: Raminta Stuikyte, et al.
Published: (2024-01-01)

Correction: Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund Support
by: Raminta Stuikyte, et al.
Published: (2024-01-01)

Medications for opioid use disorder during war in Ukraine: Innovations in public and private clinic cooperation
by: Daniel J. Bromberg, et al.
Published: (2022-09-01)

High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
by: Samy J. Galvez, et al.
Published: (2023-11-01)

Probation clients’ barriers to access and use of opioid use disorder medications
by: Jessica Reichert, et al.
Published: (2019-05-01)

Corrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
by: Samy J. Galvez, et al.
Published: (2024-01-01)

Interest without uptake: A mixed-methods analysis of methadone utilization in Kyrgyz prisons.
by: Amanda R Liberman, et al.
Published: (2022-01-01)

Opioid Agonist Treatment and Risk of Mortality During an Opioid Overdose Public Health Emergency: A Population-Based Retrospective Cohort Study
by: Lindsay A Pearce, et al.
Published: (2020-12-01)

Interim opioid agonist treatment for opioid addiction: a systematic review
by: Laura Samsó Jofra, et al.
Published: (2022-01-01)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
by: Chrianna Bharat, et al.
Published: (2022-08-01)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
by: Nathaniel Day, et al.
Published: (2022-07-01)

Therapeutic Potential of Kappa Opioid Agonists
by: Tyler C. Beck, et al.
Published: (2019-06-01)

“Medications for opioid use disorder during the war in Ukraine: a more comprehensive view on the government response—Authors’ reply”
by: Daniel J. Bromberg, et al.
Published: (2023-03-01)

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?
by: R. Weiss, et al.
Published: (2023-03-01)

Responding to health policy recommendations on managing opioid use disorder during Russia's invasion of Ukraine: Divergent responses from the frontline to the west
by: Roman Ivasiy, et al.
Published: (2023-01-01)

Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis
by: Valerie Giang, et al.
Published: (2020-08-01)

Contextualizing medications for opioid use disorder and peer support service provision in the probation system with implementation science
by: Augustine W. Kang, et al.
Published: (2024-03-01)

Serious mental illness and negative substance use consequences among adults on probation
by: Matthew E. Rossheim, et al.
Published: (2018-03-01)

Biphalin—A Potent Opioid Agonist—As a Panacea for Opioid System-Dependent Pathophysiological Diseases?
by: Patrycja Redkiewicz, et al.
Published: (2021-10-01)

Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127
by: Yuki Moriya, et al.
Published: (2023-03-01)

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study
by: Narjes Shojaati, et al.
Published: (2023-08-01)

Artificial Intelligence (AI) .. Marketing touchpoints
by: Khalida ABI, et al.
Published: (2023-09-01)

Evaluating concurrent validity of criminal justice and clinical assessments among women on probation
by: Camila D. Odio, et al.
Published: (2018-04-01)

Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study
by: Kira von Bernuth, et al.
Published: (2020-08-01)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
by: Michael Soyka
Published: (2021-11-01)

The mechanisms of ultra-low dose opioid agonist-antagonist
by: Chih-Shung Wong, MD, PhD.
Published: (2011-10-01)

<it>In vivo </it>antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
by: Guillemyn Karel, et al.
Published: (2012-01-01)

From Opioid Pain Management to Opioid Crisis in the USA: How Can Public-Private Partnerships Help?
by: Larissa Bolliger, et al.
Published: (2019-05-01)

Opioid Agonist Therapies and Pregnancy Outcomes for Pregnant People With Opioid Use Disorder: Protocol for a Systematic Review
by: Lindsay A Wilson, et al.
Published: (2023-05-01)

Problems Surrounding Probation In The South African Public Service
by: Z. Baloyi, et al.
Published: (2006-11-01)

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
by: Leah M. Salinsky, et al.
Published: (2023-10-01)

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists
by: Edina Szűcs, et al.
Published: (2020-02-01)

Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor.
by: Xiaojing Cong, et al.
Published: (2015-01-01)

Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment
by: Azbel, L., et al.
Published: (2016)

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
by: Ashish P. Thakrar, et al.
Published: (2023-02-01)